Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting
- 30 June 2009
- journal article
- research article
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 36 (4), 428-434
- https://doi.org/10.1016/j.jsat.2008.09.001
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Factor structure and validity of the Medication Adherence Questionnaire (MAQ) with cigarette smokers trying to quitNicotine & Tobacco Research, 2007
- A double-blind study evaluating the long-term safety of varenicline for smoking cessationCurrent Medical Research and Opinion, 2007
- Effects of abstinence from tobacco: Valid symptoms and time courseNicotine & Tobacco Research, 2007
- Gender differences in acute tobacco withdrawal: Effects on subjective, cognitive, and physiological measures.Experimental and Clinical Psychopharmacology, 2007
- Efficacy and Safety of the Novel Selective Nicotinic Acetylcholine Receptor Partial Agonist, Varenicline, for Smoking CessationArchives of Internal Medicine, 2006
- Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking CessationA Randomized Controlled TrialJAMA, 2006
- Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking CessationA Randomized Controlled TrialJAMA, 2006
- PharmGKB Update: I. Genetic Variants of the Organic Cation Transporter 2 (OCT2, SLC22A2)Pharmacological Reviews, 2003
- Gender differences in smoking cessation.Journal of Consulting and Clinical Psychology, 1999
- Gender differences in smoking cessation.Journal of Consulting and Clinical Psychology, 1999